My name is Michael Raddatz, and I am a cardiology fellow and physician-scientist at UCLA. I completed my PhD in Biomedical Engineering as part of the Vanderbilt MSTP supported by an NIH/NHLBI F30 predoctoral fellowship. My work has used in vitro, in vivo, and in silico approaches to define contributions of hematopoietic cells and inflammation to valvular calcification. Recent work with Alex Bick, MD, PhD at Vanderbilt has investigated the causes and consequences of clonal hematopoiesis of indeterminate potential (CHIP) and how this relates to cardiovascular morbidity. I am currently working with Jake Lusis, PhD to define and therapeutically target macrophage metabolism in atherosclerosis. I am broadly interested in finding ways to modulate the hematopoietic system to treat cardiovascular disease.